Mr. William Gastle reports

MICROBIX ANNOUNCES LEADERSHIP TRANSITION

Microbix Biosystems Inc. has appointed Cameron Groome as its president and chief executive officer, with Vaughn Embro-Pantalony retiring from those positions but remaining an executive director, working closely with Mr. Groome to ensure a smooth leadership transition.

Mr. Groome has been in the life sciences industry for more than 25 years, as a chief executive officer, director, adviser, senior executive, investment banker and equity research analyst. He has been successful in operating, advising, financing and analyzing life sciences companies and has been a member of the board of directors and the audit committee of Microbix for the past five years. Mr. Groome is also a director of ScarX Therapeutics Corp. (Toronto), Naegis Pharmaceuticals Ltd. (Vancouver) and a member of the Global Affairs Canada life sciences advisory group (Ottawa).

William J. Gastle, founder and executive chairman of Microbix, welcomed Mr. Groome to the chief executive officer position at Microbix, stating: "We are pleased to have Cameron join us in this capacity. His abilities and knowledge of life sciences and Microbix should help drive us to greater success."

Mr. Gastle also thanked Mr. Embro-Pantalony for his service, noting: "We deeply appreciate Vaughn's work as CEO over the past five years, during which time our virology-related sales have more than doubled to approximately $10-million per year, strengthening our operating results and overall financial position. Also under Vaughn's leadership, Microbix recently completed a consultation with the U.S. Food and Drug Administration, which positions us to conclude an agreement to enable the relaunch of Kinlytic Urokinase. We thank Vaughn for his many contributions, which we continue to welcome from him as a director."

Mr. Embro-Pantalony commented on his decision to step down, stating: "It has been a privilege to lead Microbix and work with such a dedicated and passionate group of professionals. It is with pride that I leave the CEO role with Microbix well-established as a global leader in the production of viruses for use in diagnostic tests or for quality control validation. I now look forward to continuing to aid Microbix as a director while spending more time with my family as well as working on other personal and professional interests."

Mr. Groome also provided his views: "I am delighted to undertake the roles of president and CEO at Microbix and work to build value for its shareholders. Our company has exciting opportunities for growth, including in its virology business, with its thrombolytic drug, Kinlytic Urokinase and for Lumisort cell-sorting technology. It is a privilege to be appointed to lead the Microbix team and help realize the company's full potential."

About Microbix Biosystems Inc.

Microbix specializes in the development of proprietary biological and technology solutions for human health and well-being in the global therapeutic, vaccine and diagnostic markets. The company manufactures a wide range of highly purified infectious microorganism antigens for the global diagnostics industry, with sales of approximately $10-million per year. The company also applies its biological expertise and technology platforms to create other innovative products and technologies.

We seek Safe Harbor.